-

11:19:23 AM

Latest ADMP Stock Market News

ADMP - Adamis Pharmaceuticals Corp

06/14/21 9:00 AM

Nasdaq : ADMP

Adamis Files Definitive Proxy Statement and Sends Letter to Stockholders

Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced that it has filed its definitive proxy statement with the U.S. Securities and Exchange Commission and sent the below letter to stockholders. The letter has been signed by all five members of the Company’s Board of Directors: Howard

RHEA-AI

neutral

06/11/21 7:30 AM

Nasdaq : ADMP

Adamis Provides Update on Clinical Trial Start-Up Progress for Tempol in the Treatment of COVID-19

Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced that clinical trial start-up activities are underway for examining the effects of

RHEA-AI

neutral

06/09/21 7:30 AM

Nasdaq : ADMP

Adamis Provides Update on ZIMHI™

Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the

RHEA-AI

neutral

06/07/21 7:30 AM

Nasdaq : ADMP

Adamis Highlights National Institute of Health Study Identifying Tempol as a Potential Antiviral Drug for COVID-19

Adamis Pharmaceuticals

RHEA-AI

neutral

06/01/21 7:30 AM

Nasdaq : ADMP

Adamis Pharmaceuticals Provides Business Update

Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a biopharmaceutical company developing and commercializing specialty products

RHEA-AI

neutral

05/28/21 4:04 PM

Nasdaq : ADMP

Adamis Pharmaceuticals Announces Receipt of Deficiency Letter from NASDAQ

Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a biopharmaceutical company developing and commercializing specialty products for respiratory disease, allergy and opioid overdose (the “Company”), today announced that, as expected, on May 25, 2021, it

RHEA-AI

very positive

05/17/21 4:05 PM

Nasdaq : ADMP

Adamis Pharmaceuticals Provides Update on First Quarter 2021 Financial Results Conference Call

Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced that it is postponing its previously announced investor conference call scheduled to be held on Monday, May 17, 2021, at 2 p.m. Pacific Time. The company filed a Form 12b-25 with the

RHEA-AI

neutral

05/17/21 7:30 AM

Nasdaq : ADMP

Adamis Pharmaceuticals Resubmits ZIMHI New Drug Application to FDA for the Treatment of Opioid Overdose

Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a biopharmaceutical company developing and commercializing specialty products for respiratory disease, allergy and opioid overdose, today announced that the New Drug Application (NDA) was resubmitted to

RHEA-AI

neutral

05/12/21 7:30 AM

Nasdaq : ADMP

Adamis Pharmaceuticals Schedules First Quarter 2021 Financial Results Conference Call and Business Update

Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a biopharmaceutical company developing and commercializing specialty products for respiratory disease, allergy and opioid overdose, today announced that it will host an investor conference call on

RHEA-AI

neutral

04/15/21 4:39 PM

Nasdaq : ADMP

Adamis Pharmaceuticals Announces 2020 Financial Results and Business Update

Adamis Pharmaceuticals

RHEA-AI

neutral

ADMP Data

industryPharmaceutical Preparation Manufacturing
websitewww.adamispharmaceuticals.com
ceoDennis Carlo
security nameAdamis Pharmaceuticals Corp
issue typecs
sectorManufacturing
sic code2834
employees
tagsHealth Technology,Pharmaceuticals: Other,Pharmaceuticals: Major,Manufacturing,Pharmaceutical Preparation Manufacturing
address11682 El Camino Real Ste 300
address2
stateCalifornia
citySan Diego
zip92130
countryUS
phone18589972400

ADMP Description:

Adamis Pharmaceuticals Corporation is a specialty biopharmaceutical company primarily focused on developing and commercializing products in various therapeutic areas, including allergy, opioid overdose, respiratory and inflammatory disease. The company's SYMJEPI (epinephrine) Injection products are approved by the FDA for use in the emergency treatment of acute allergic reactions, including anaphylaxis. Adamis' naloxone injection product candidate, ZIMHI, for the treatment of opioid overdose is currently under FDA review. Adamis is developing additional products, including treatments for acute respiratory diseases, such as COVID-19, influenza, asthma, and COPD. The company's subsidiary, US Compounding Inc., compounds sterile prescription drugs, and certain nonsterile drugs for human and veterinary use by hospitals, clinics, surgery centers, and vet clinics throughout most of the United States. Forward Looking Statements